Over the past few years, the demand for Ozempic as an aid in shedding pounds has skyrocketed. Numerous celebrities worldwide have experienced remarkable reductions in weight within brief periods thanks to its effects.
Although Ozempic represents the brand name, the active substance is known as GLP-1 or GLP-1 agonists. This abbreviation stands for glucagon-like peptide-1 receptor agonists, which, per Harvard Health, replicate the GLP-1 hormone naturally produced in the esophagus after meals.
GLP-1 stimulates insulin secretion from the pancreas, facilitating the movement of glucose from the blood into cells for fuel and sustenance. The primary mechanism behind weight reduction involves the medication's influence on the brain, where it diminishes appetite, and on the stomach, where it slows digestion.
Nonetheless, growing worries exist regarding the short-lived nature of GLP-1 drugs, as users report regaining shed pounds shortly after halting treatment. On January 12, Dr. Karan Rajan, a surgeon based in the UK and creator of health-related content, addressed this issue via Instagram.
As per Dr. Rajan, numerous people who discontinued GLP-1 medications have experienced a return of the weight they previously lost.
"Research involving more than 9,000 participants indicated that individuals who ceased taking newer GLP-1 drugs saw a weight increase of roughly 0.8 kilograms, or 1.8 pounds, each month," he noted. "Typically, they reverted to their initial weight within approximately 1.5 years."
Yet, the physician views this weight restoration not as a shortcoming of the pharmaceuticals. He maintains that GLP-1s perform precisely as intended, and the regained pounds merely illustrate obesity's characteristics as a persistent, recurring ailment.


